Study of Elironrasib (RMC-6291) and Daraxonrasib (RMC-6236) With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol A

Brief summary (registry, in English)

To evaluate the safety and tolerability of elironrasib in combination with pembrolizumab, with or without daraxonrasib, with or without chemotherapy, in patients with advanced RAS G12C-mutated solid tumors To define the RP2DS for elironrasib in combination with pembrolizumab, with or without daraxonrasib, with or without chemotherapy, in patients with advanced RAS G12C-mutated NSCLC

What you commit to

• Study type: Interventional · Phase 1
• Planned participants: 330
• 41 sites in 5 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a solid tumor that has a RAS G12C change, including non-small cell lung cancer. People must have had earlier cancer treatment or be unable to tolerate regular treatments.

Age

18 years or older, or the legal age of consent.

Sex

All sexes can join.

Disease stage

Solid tumor with RAS G12C and at least one tumor lesion that can be measured.

Earlier treatment

Must have had prior cancer treatment or be unable to tolerate regular treatments. Cannot have taken targeted therapy for a KRAS mutation before.

Biomarker or test result

RAS G12C mutation.

Main reasons for not taking part

• Primary brain or spinal cord tumor
• Gastrointestinal problems that may affect absorption of elironrasib
• Any major surgery in the last 4 weeks
• Earlier targeted therapy for a KRAS mutation
• Other medical conditions, medicines, foods or treatments that may interfere with the study drugs

Read by machine on 9 Nov 2026.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (41)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details